HIV Prevention Drug Coming to Highest Risk Patients at No Cost

June 11, 2019, 3:00 PM

People at highest risk for HIV will soon have access to the only drug to prevent infections with no out-of-pocket expenses under their employer-sponsored health plans.

The U.S. Preventive Services Task Force June 11 gave the HIV prevention medication, also known as pre-exposure prophylaxis or PrEP, an A grade, the highest coverage recommendation it can make. Under the Affordable Care Act, private insurance plans are obligated to cover—at no cost to the patient—preventive services the task force awards A or B grades.

Truvada, which is manufactured by Gilead Sciences, is currently the only drug approved for PrEP in the U.S. ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.